Board WHOcte. Soft tissue and bone tumours. 5th ed. World Health Organization Classification of tumours. World Health Organization International Agency for Research on Cancer; 2020.

Muheremu A, Niu X. Pulmonary metastasis of giant cell tumor of bones. World J Surg Oncol. 2014;12:261. https://doi.org/10.1186/1477-7819-12-261.

Article  PubMed  PubMed Central  Google Scholar 

Aoude A, Nikomarov D, Perera JR, Ibe IK, Griffin AM, Tsoi KM, et al. Giant cell tumour of bone. Bone Joint J. 2023;105-b(5):559–67. https://doi.org/10.1302/0301-620x.105b5.Bjj-2022-1231.R1.

Article  PubMed  Google Scholar 

Lopez-Pousa A, Martin Broto J, Garrido T, Vazquez J. Giant cell tumour of bone: new treatments in development. Clin Transl Oncol. 2015;17(6):419–30. https://doi.org/10.1007/s12094-014-1268-5.

Article  PubMed  PubMed Central  Google Scholar 

Noh BJ, Park YK. Giant cell tumor of bone: updated molecular pathogenesis and tumor biology. Hum Pathol. 2018;81:1–8. https://doi.org/10.1016/j.humpath.2018.06.017.

Article  PubMed  Google Scholar 

Lutsik P, Baude A, Mancarella D, Oz S, Kuhn A, Toth R, et al. Globally altered epigenetic landscape and delayed osteogenic differentiation in H3.3–G34W-mutant giant cell tumor of bone. Nat Commun. 2020;11(1):5414. https://doi.org/10.1038/s41467-020-18955-y.

Article  PubMed  PubMed Central  Google Scholar 

Fellenberg J, Sahr H, Mancarella D, Plass C, Lindroth AM, Westhauser F, et al. Knock-down of oncohistone H3F3A-G34W counteracts the neoplastic phenotype of giant cell tumor of bone derived stromal cells. Cancer Lett. 2019;448:61–9. https://doi.org/10.1016/j.canlet.2019.02.001.

Article  PubMed  Google Scholar 

Hu P, Zhao L, Zhang H, Yu X, Wang Z, Ye Z, et al. Recurrence rates and risk factors for primary giant cell tumors around the knee: a multicentre retrospective study in China. Sci Rep. 2016;6:36332. https://doi.org/10.1038/srep36332.

Article  PubMed  PubMed Central  Google Scholar 

Ng VY, Davidson DJ, Kim EY, Pollack SM, Conrad Iii EU, Jones RL. The multidisciplinary management of giant cell tumor of bone. Expert Rev Anticancer Ther. 2014;14(7):783–90. https://doi.org/10.1586/14737140.2014.901891.

Article  PubMed  Google Scholar 

Balke M, Ahrens H, Streitbuerger A, Koehler G, Winkelmann W, Gosheger G, et al. Treatment options for recurrent giant cell tumors of bone. J Cancer Res Clin Oncol. 2009;135(1):149–58. https://doi.org/10.1007/s00432-008-0427-x.

Article  PubMed  Google Scholar 

van Langevelde K, Cleven AHG, Navas Cañete A, van der Heijden L, van de Sande MAJ, Gelderblom H, et al. Malignant transformation of giant cell tumor of bone and the association with denosumab treatment: a radiology and pathology perspective. Sarcoma. 2022;2022:3425221. https://doi.org/10.1155/2022/3425221.

Article  PubMed  PubMed Central  Google Scholar 

Li H, Gao J, Gao Y, Lin N, Zheng M, Ye Z. Denosumab in giant cell tumor of bone: current status and pitfalls. Front Oncol. 2020;10: 580605. https://doi.org/10.3389/fonc.2020.580605.

Article  PubMed  PubMed Central  Google Scholar 

van der Heijden L, Lipplaa A, van Langevelde K, Bovée J, van de Sande MAJ, Gelderblom H. Updated concepts in treatment of giant cell tumor of bone. Curr Opin Oncol. 2022;34(4):371–8. https://doi.org/10.1097/cco.0000000000000852.

Article  PubMed  Google Scholar 

Hattori E, Oyama R, Kondo T. Systematic review of the current status of human sarcoma cell lines. Cells. 2019;8(2):157. https://doi.org/10.3390/cells8020157.

Article  PubMed  PubMed Central  Google Scholar 

Goodspeed A, Heiser LM, Gray JW, Costello JC. Tumor-derived cell lines as molecular models of cancer pharmacogenomics. Mol Cancer Res. 2016;14(1):3–13. https://doi.org/10.1158/1541-7786.Mcr-15-0189.

Article  PubMed  Google Scholar 

Liu L, Aleksandrowicz E, Fan P, Schönsiegel F, Zhang Y, Sähr H, et al. Enrichment of c-Met+ tumorigenic stromal cells of giant cell tumor of bone and targeting by cabozantinib. Cell Death Dis. 2014;5(10): e1471. https://doi.org/10.1038/cddis.2014.440.

Article  PubMed  PubMed Central  Google Scholar 

Bairoch A. The Cellosaurus, a cell-line knowledge resource. J Biomol Tech. 2018;29(2):25–38. https://doi.org/10.7171/jbt.18-2902-002.

Article  PubMed  PubMed Central  Google Scholar 

Noguchi R, Yoshimatsu Y, Ono T, Sei A, Hirabayashi K, Ozawa I, et al. Establishment and characterization of NCC-GCTB1-C1: a novel patient-derived cancer cell line of giant cell tumor of bone. Hum Cell. 2020;33(4):1321–8. https://doi.org/10.1007/s13577-020-00415-w.

Article  PubMed  Google Scholar 

Yoshimatsu Y, Noguchi R, Tsuchiya R, Ono T, Sin Y, Akane S, et al. Establishment and characterization of novel patient-derived cell lines from giant cell tumor of bone. Hum Cell. 2021;34(6):1899–910. https://doi.org/10.1007/s13577-021-00579-z.

Article  PubMed  Google Scholar 

Ono T, Noguchi R, Yoshimatsu Y, Tsuchiya R, Sin Y, Nakagawa R, et al. Establishment and characterization of the NCC-GCTB4-C1 cell line: a novel patient-derived cell line from giant cell tumor of bone. Hum Cell. 2022;35(1):392–9. https://doi.org/10.1007/s13577-021-00639-4.

Article  PubMed  Google Scholar 

Akiyama T, Yoshimatsu Y, Noguchi R, Sin Y, Tsuchiya R, Ono T, et al. Establishment and characterization of NCC-GCTB5-C1: a novel cell line of giant cell tumor of bone. Hum Cell. 2022;35(5):1621–9. https://doi.org/10.1007/s13577-022-00724-2.

Article  PubMed  Google Scholar 

Ono T, Noguchi R, Yoshimatsu Y, Sin Y, Tsuchiya R, Akiyama T, et al. Establishment and characterization of two novel patient-derived cell lines from giant cell tumor of bone. Hum Cell. 2023;36(5):1804–12. https://doi.org/10.1007/s13577-023-00928-0.

Article  PubMed  Google Scholar 

Adachi Y, Noguchi R, Yoshimatsu Y, Sin Y, Osaki J, Ono T, et al. Establishment and characterization of two novel patient-derived cell lines from giant cell tumor of bone: NCC-GCTB8-C1 and NCC-GCTB9-C1. Hum Cell. 2024. https://doi.org/10.1007/s13577-024-01042-5.

Article  PubMed  Google Scholar 

Girolami I, Mancini I, Simoni A, Baldi GG, Simi L, Campanacci D, et al. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series. J Clin Pathol. 2016;69(3):240–7. https://doi.org/10.1136/jclinpath-2015-203248.

Article  PubMed  Google Scholar 

Shibuya I, Takami M, Miyamoto A, Karakawa A, Dezawa A, Nakamura S, et al. In vitro study of the effects of denosumab on giant cell tumor of bone: comparison with zoledronic acid. Pathol Oncol Res. 2019;25(1):409–19. https://doi.org/10.1007/s12253-017-0362-8.

Article  PubMed  Google Scholar 

Rutkowski P, Gaston L, Borkowska A, Stacchiotti S, Gelderblom H, Baldi GG, et al. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - multicenter analysis outside clinical trial. Eur J Surg Oncol. 2018;44(9):1384–90. https://doi.org/10.1016/j.ejso.2018.03.020.

Article  PubMed  Google Scholar 

Palmerini E, Staals EL, Jones LB, Donati DM, Longhi A, Randall RL. Role of (neo)adjuvant denosumab for giant cell tumor of bone. Curr Treat Options Oncol. 2020;21(8):68. https://doi.org/10.1007/s11864-020-00766-4.

Article  PubMed  Google Scholar 

Lau CP, Huang L, Wong KC, Kumta SM. Comparison of the anti-tumor effects of denosumab and zoledronic acid on the neoplastic stromal cells of giant cell tumor of bone. Connect Tissue Res. 2013;54(6):439–49. https://doi.org/10.3109/03008207.2013.848202.

Article  PubMed  Google Scholar 

Mukaihara K, Suehara Y, Kohsaka S, Akaike K, Tanabe Y, Kubota D, et al. Protein expression profiling of giant cell tumors of bone treated with denosumab. PLoS One. 2016;11(2): e0148401. https://doi.org/10.1371/journal.pone.0148401.

Article  PubMed  PubMed Central  Google Scholar 

Errani C, Tsukamoto S, Leone G, Righi A, Akahane M, Tanaka Y, et al. Denosumab may increase the risk of local recurrence in patients with giant-cell tumor of bone treated with curettage. J Bone Joint Surg Am. 2018;100(6):496–504. https://doi.org/10.2106/jbjs.17.00057.

Article  PubMed  Google Scholar 

Toda Y, Kohashi K, Yamamoto H, Ishihara S, Ito Y, Susuki Y, et al. Tumor microenvironment in giant cell tumor of bone: evaluation of PD-L1 expression and SIRPα infiltration after denosumab treatment. Sci Rep. 2021;11(1):14821.